The Texas Heart Institute Center for Cardiovascular Care has divulged piperazine-based integrin αLβ2 (LFA-1) and/or integrin α4β1 (ITGA4; VLA-4) agonists reported to be useful for the treatment of diabetes, infertility, pulmonary hypertension, renal failure, myocardial infarction, spinal cord injury, pulmonary fibrosis and Parkinson's diseases.
A lot of focus has been put on targeting T-cell immunoreceptor with Ig and ITIM domains (TIGIT) for HIV infection treatment, but no attention has been given to targeting its ligand, CD155.
Antiretroviral (ARV) therapy suppresses HIV, but viral replication rebounds once treatment is discontinued. The redistribution of lipids in the plasma membrane to form microdomains is crucial for viral entry and biogenesis during HIV infection. Researchers at Johns Hopkins University School of Medicine found neutral sphingomyelinase 2 (nSMase2) to be a key component of the late stages of HIV viral assembly and maturation; they hypothesized that nSMase2 inhibitors could help avoid viral rebound.
Flagship Pioneering Inc. has unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable and effective by acting at the site of disease. Flagship has initially committed US$50 million to advance Ampersand's Address, Navigate, Design (AND) Platform and develop an initial pipeline of medicines across a range of disease areas.
Researchers from the Brigham and Women’s Hospital and Harvard Medical School and collaborators recently conducted a study investigating the regulation of immune checkpoint molecules in cancer. Analyzing data from The Cancer Genome Atlas pan-cancer cohort (over 10,000 patients and 11,000 samples across 34 different cancer subtypes), they found that high expression of the immune checkpoint B7-H3 (CD276) and high mTORC1 activity correlate with immunosuppressive phenotypes and worse clinical outcomes.
RSS
